Biphasic insulin aspart 30 (BIAsp 30) in clinical reality: Experience from a Dutch practice

被引：0
|
作者：
Ligthelm, Robert J.
机构：
来源：
DIABETES | 2007年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A540 / A540
页数：1
相关论文
共 50 条
  • [1] The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin aspart 30 (BIAsp 30)
    Bott, S
    Tusek, C
    Heinemann, L
    Friberg, HH
    Heise, T
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (09) : 545 - 550
  • [2] Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
    Valensi, Paul
    DIABETES METABOLIC SYNDROME AND OBESITY, 2009, 2 : 61 - 71
  • [3] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    DIABETES, 2006, 55 : A460 - A461
  • [4] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
    Liebl, A.
    Compion, G.
    Prager, R.
    Binz, K.
    Kaiser, M.
    Gallwitz, B.
    DIABETIC MEDICINE, 2007, 24 : 75 - 75
  • [5] Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects
    Hassan, Mohammad Imtiaz
    Aamir, Azizul Hasan
    Miyan, Zahid
    Siddiqui, Laiq Ahmed
    Mahmood, Shahid
    Vohra, Ejaz Ahmed
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2013, 63 (10) : 1290 - 1294
  • [6] A COMPARISON OF BIPHASIC INSULIN ASPART (BIASP30) WITH BIPHASIC HUMAN INSULIN (BHI30) FOR TYPE 2 DIABETES MELLITUS IN REAL CLINICAL PRACTICE - A SYSTEMATIC REVIEW AND META-ANALYSIS
    Wojciechowski, P.
    Gaweska, M.
    Caban, A.
    Jurkiewicz, B.
    Plisko, R.
    Rys, P.
    VALUE IN HEALTH, 2013, 16 (03) : A157 - A157
  • [7] Biphasic Insulin Aspart 30 (BIAsp 30) is Safe and Improves Glycaemic Control in Insulin Naive Patients with Type 2 Diabetes
    Esteghamati, Alireza
    Nakhjavani, Manouchehr
    Aminorroaya, Ashraf
    Aboutorabi, Robabeh
    Niafar, Mitra
    Mohammadi, Mohammad
    Parvaresh, Ehsan
    JOURNAL OF DIABETES & METABOLISM, 2011, 2 (03)
  • [8] Significant Improvements in Glycemic Control with BIAsp 30 in Clinical Reality: Experience from Clinical Practice in Macedonia
    Milenkovic, Tatjana
    Smokovski, Ivica
    Kulumova, Elena
    Stojanovski, Nikola
    Aleksov, Branko
    DIABETES, 2009, 58 : A536 - A536
  • [9] Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study
    Morgan, Christopher Li
    Evans, Marc
    Toft, Anders D.
    Jenkins-Jones, Sara
    Poole, Chris D.
    Currie, Craig J.
    CLINICAL THERAPEUTICS, 2011, 33 (01) : 27 - 35
  • [10] Use of a New Basal Insulin with a Bolus Boost (IDegAsp) in Type 2 Diabetes: Comparison with Biphasic Insulin Aspart 30 (BIAsp 30)
    Vaag, Allan
    Leiter, Lawrence A.
    Franek, Edward
    Weng, Jianping
    Damci, Taner
    Munoz Torres, Manuel
    Donnet, Jean-Paul
    Endahl, Lars
    Skjoth, Trine V.
    Niskanen, Leo
    DIABETES, 2011, 60 : A313 - A313
12345